Podocytes as target of vitamin D

Current Diabetes Reviews

Volumn 7, Issue 1, 2011, Pages 35-40

  Li, Yan C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chronic kidney disease; Diabetic nephropathy; Podocyte; Vitamin D; Vitamin d analog

Indexed keywords

BETA CATENIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; NEPHRIN; PARICALCITOL; PLACEBO; VITAMIN D; VITAMIN D DERIVATIVE; WNT PROTEIN;

ALBUMINURIA; APOPTOSIS; BONE DISEASE; BONE MINERAL; CELL LOSS; CELL PROTECTION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HUMAN; HYPERTROPHY; HYPOCALCEMIA; KIDNEY FAILURE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY HYPERPARATHYROIDISM; TARGET CELL; VITAMIN D DEFICIENCY;

EID: 79952742829     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339911794273964     Document Type: Review

References (58)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
2. Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96: 507-515.
3. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
4. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95.
5. KE White, WE Evans, JLH O'Riordan et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26: 345-348.
6. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505.
7. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
8. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-1946.
9. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279.
10. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256.
11. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1150.
12. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
13. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403.
14. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
15. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
16. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76: 977-983.
17. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
18. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29: 726-776.
19. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.
20. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
21. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13: 325-349.
22. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004-1110.
23. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50: 69-77.
24. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
25. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albu-minuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
26. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394-1402.
27. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subto-tally nephrectomized rats. Kidney Int 1998; 53:1696-1705.
28. Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806.
29. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-533.
30. Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163-171.
31. Zhang Y, Kong J, Ning G, et al. Long-Term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiology 2009; 297: F791-F801.
32. Li YC. Renoprotective effects of vitamin D analogs. Kidney Int 2010; 78(2): 134-139.
33. Deb DK, Sun T, Wong KE, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of Type 2 diabetes. Kidney Int 2010; 77(11): 1000-1009.
34. Wang Y, Zhou J, Minto AW, et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int 2006; 70: 882-891.
35. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274-281.
36. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
37. Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulo-sclerosis in transgenic rats. J Am Soc Nephrol 2004; 15: 1475-1487.
38. Durvasula RV, Shankland SJ. Activation of a local renin angio-tensin system in podocytes by glucose. Am J Physiol Renal Physiol 2008; 294: F830-839.
39. Yoo TH, Li JJ, Kim JJ, et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007; 71: 1019-1027.
40. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88: 327-331.
41. Yuan W, Pan W, Kong J, et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830.
42. Deb DK, Chen Y, Zhang Z, et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol 2009; 296: F1212-1218.
43. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179.
44. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105: 15896-15901.
45. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
46. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113.
47. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin signaling promotes podocyte dysfunction and al-buminuria. J Am Soc Nephrol 2009; 20: 1997-2008.
48. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001; 154: 369-387.
49. Shah S, Islam MN, Dakshanamurthy S, et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 2006; 21: 799-809.
50. Nagata M, Shu Y, Tomari S. Role of cell cycle molecules in the pathophysiology of glomerular epithelial cells. Microsc Res Tech 2002; 57: 203-207.
51. Dai T, Natarajan R, Nast CC, et al. Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney Int 2006; 69: 806-814.
52. Diker-Cohen T, Koren R, Ravid A. Programmed cell death of stressed keratinocytes and its inhibition by vitamin D: the role of death and survival signaling pathways. Apoptosis 2006; 11: 519-534.
53. Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006; 66: 4516-4524.
54. Xiao H, Shi W, Liu S, Wang W, Zhang B, Zhang Y, Xu L, Liang X, Liang Y: 1,25-Dihydroxyvitamin D(3) prevents puromycin ami-nonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am J Nephrol 2009; 30: 34-43.
55. Ding G, Reddy K, Kapasi AA, et al. Angiotensin II induces apop-tosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 283: F173-180.
56. Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65: 30-9.
57. Takano Y, Yamauchi K, Hiramatsu N, et al. Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am J Physiol Renal Physiol 2007; 292: F1573-1582.
58. Huber TB, Hartleben B, Kim J, et al. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol 2003; 23: 4917-4928.